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Introduction: Inadequately controlled severe asthma patients require additional therapy
accounting for significant clinical and economic burden. Our analysis aims to determine the
cost-effectiveness of omalizumab in the management of severe allergic asthma in Italy based
on observational data from the PROXIMA study.
Methods: Observational data on efficacy, healthcare resource utilization and changes in
quality of life at 12 months after the initiation of omalizumab were examined to estimate the
cost-effectiveness compared to pre-omalizumab period and results were expressed with
Incremental Cost-Effectiveness Ratio (ICER). The cost–utility analysis estimated the cost
per quality-adjusted life-year (QALY) gained. Direct health costs were assessed from the
perspective of the Italian National Health Service (NHS).
Results: Omalizumab reduced the incidence of exacerbations, number of hospitalizations, phy-
sician visits, and improved quality of life after 12 months of treatment. Omalizumab had a greater
effectiveness than pre-omalizumab treatment involving 0.132 QALYs gained and led to a €3729
per patient reduction in direct healthcare costs, excluding the add-on treatment cost. Nevertheless,
the addition of omalizumab cost led to €7478 increase in total direct costs with respect to pre-
omalizumab period. Based on difference in total direct cost and difference in QALY between post
and pre-omalizumab period, the ICERwas €56,847. According to sensitivity analysis, omalizumab
provided a cost-effective use of NHS resources, already at 20% discounted price.
Conclusion: This study offers a real-world evidence of omalizumab effectiveness in Italy.
Despite the high acquisition cost of the innovative drug, omalizumab is a sustainable
treatment option for patients with uncontrolled severe allergic asthma.
Keywords: severe allergic asthma, healthcare costs, effectiveness, cost-utility, omalizumab,
PROXIMA study
Introduction
Asthma is a common chronic respiratory disorder, with more than 300 million
patients worldwide, it is one of the major non-communicable diseases and a global
public health problem.1
In Italy, the median prevalence of asthma was reported to be 6.6%, recording a
35% increase in the last two decades.2 The disease is characterized by chronic
airway inflammation and it is defined by the history of respiratory symptoms such
as wheeze, shortness of breath, chest tightness and cough that vary over time and in
intensity, together with variable expiratory airflow limitation.1 Asthma is a hetero-
geneous disease; it has significant genetic and environmental components. Many
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phenotypes have been identified and allergic asthma,
resulted from the overexpression of immunoglobulin E
(IgE) in response to perennial or seasonal allergens, is
the most easily recognized asthma phenotype affecting
more than 60% of patients with asthma.2–4 Disease sever-
ity is defined retrospectively according to the level of
treatment required to achieve a good asthma control,
both symptom control and future risk of exacerbations. It
can be assessed once the patient has been on controller
treatment for several months and, if appropriate, treatment
step down has been attempted to find the patient’s mini-
mum effective level of treatment. Asthma severity is not a
static feature and may change over months or years.5
Treatment options include inhaled and systemic corti-
costeroids (ICS, OCS), leukotriene receptor antagonist,
long-acting inhaled β2 agonist bronchodilator (LABA)
and IgE antibody. The goal of the treatment is the
achievement and the maintenance of the disease control
and the minimization of future risk of exacerbations,
following a stepwise approach.1,5 Increasing asthma
severity and morbidity are associated with impaired qual-
ity of life, work productivity loss, greater mortality risk
and higher health care resource utilization and costs.6–9
Asthma-related costs vary from country to country and
disease severity. An international review reports a mean
cost per patient per year, including all asthmatics (inter-
mittent, mild, moderate and severe asthma) between
$USD 1900 in Europe and $USD 3100 in USA.10 As
evidence of the high costs associated with severe stages
of the disease, a recent Spanish study has estimated a
mean annual direct cost per patient equal to €7472, and
when indirect costs were considered, the total mean
annual cost rose to €8554.11 As regard Italy, severe
refractory asthma, occurring in patients not achieving
disease control despite high-intensity therapy, good
adherence and proper inhalation technique, has been
associated with annual costs per patient amounting to
€2815, including drug treatment, hospitalization and out-
patient services.12 Moreover, findings of a recent online
survey completed by employed adults in Brazil, Canada,
Germany, Japan, Spain and the UK reported an impact on
productivity at work caused by asthma in nearly three-
quarters of patients. Overall work productivity loss (both
time off and productivity whilst at work) due to asthma
was 36%, ranging from 21% (UK) to 59% (Brazil).13
Despite effective treatments and management guidelines,
5–10% of asthmatics suffer from severe asthma (SA) and
it accounts for 50% of the global costs of the disease.14–17
Although treatment with daily high-dose inhaled corti-
costeroids (ICSs) and long-acting inhaled β2 agonists
(LABAs), a significant proportion of SA patients do not
achieve a good disease control requiring additional
therapy.18–20 For those patients, omalizumab, a recombi-
nant DNA-derived humanized monoclonal antibody that
selectively binds to human immunoglobulin E (IgE), is an
add-on treatment approved in Europe in adults, adoles-
cents and children (6–<12 years of age) with severe
persistent allergic asthma inadequately controlled.21 In
several clinical studies, omalizumab has been shown to
improve asthma control and reduce exacerbations in
patients with inadequately controlled severe allergic
asthma.22–27 Moreover, add-on omalizumab demon-
strated improvements in symptoms and asthma-related
quality of life and reduction of medical resource utiliza-
tion (hospitalizations, emergency room visits and use of
corticosteroids and rescue bronchodilators).28–32 The
effectiveness and safety of omalizumab in severe allergic
asthma management were also shown in different real-
world settings.33–44 In Italy, the PROXIMA (Patient
Reported Outcomes and Xolair® In the Management of
Asthma) study, an observational, multicenter, cross-sec-
tional and prospective cohort study was conducted at 25
centers in outpatients settings (Table S1). The aims were
to estimate the prevalence of perennial allergy in adult
patients with severe allergic asthma and to evaluate
asthma control and treatment adherence up to 12 months
in patients treated with omalizumab. The study also
aimed to describe patient’s perception toward allergic
asthma, incidence of asthma exacerbations, patient’s
compliance and persistence with omalizumab, healthcare
resources utilization and quality of life during a 12-month
period of treatment in longitudinal population. In addi-
tion, an ancillary study was carried out to explore asthma
protein biomarkers in biologic samples and to assess a
correlation with the achievement and maintenance of
disease control.45 Focusing on healthcare resource utili-
zation and quality of life results of PROXIMA Study, we
carried out an economic evaluation of omalizumab treat-
ment. Economic evaluations are essential for health
decision-making, comparison of costs and additional ben-
efits of new health technologies, and calculation of
whether their use is an efficient use of resources.46,47
Omalizumab, as biological drug, is more expensive than
standard treatments but, due to its efficacy and safety,
offers an improvement in the management of the disease
allowing an alternative to maintenance therapy with
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high-dose corticosteroids (ICS/OCS) for uncontrolled
patients. This study aimed to evaluate the economic
value of omalizumab in the treatment of adult patients
with severe asthma in an Italian setting based on real-
world data from the PROXIMA Study.
Methods
Study Design
Using the data available from the PROXIMA study, an
economic analysis was conducted to evaluate the cost-effec-
tiveness of omalizumab in the management of severe allergic
asthma in Italy. The analysis was carried out from the Italian
National Health Service (INHS) perspective, including only
direct health costs. The time horizon was the 12-month
follow-up period, planned in the observational study for the
longitudinal phase. Costs and outcomes of treatment were
assessed at baseline (pre-omalizumab treatment period) and
at 12 months after the initiation of omalizumab (post omali-
zumab treatment period). The aim of the study has been to
compare the cost, clinical and quality of life data referring to
the population selected for the longitudinal phase before and
after starting treatment with omalizumab, to evaluate the
overall effect of the therapy.
Clinical Data Input: PROXIMA Study
The PROXIMA study design and methods have been
described in depth previously.45 Briefly, it was an observa-
tional, multicenter study structured in 2 phases, cross-sec-
tional and a longitudinal phase. In the cross-sectional
phase, study population was composed of patients aged
≥18 years, diagnosed with severe allergic asthma, who
were at step 4 as per GINA guidelines and required a
therapeutic step-up. Patients who started treatment with
omalizumab as per clinician judgement (according to
AIFA criteria) at baseline visit were included in the long-
itudinal phase. Patients started omalizumab treatment not
earlier than 15 days before enrolment, and within 90 days
after enrolment and were followed-up for 12 months. The
sample size was determined based on feasibility criteria.
The study lasted from December 2013 until June 2016; the
follow-up period consisted of two visits: the first visit after
6 months and the second one after 12 months from the
baseline (Figure 1).
The study complied with the Declaration of Helsinki,
and the AIFA (Agenzia Italiana del Farmaco) guidelines
for the classification and management of observational
studies on drugs.48 Eligible patients were enrolled only
after providing the written informed consent. The ethics
committees and institutional review boards of all partici-
pating centres approved the study documents, including
protocol and informed consent forms.
The two primary outcomes of the study were the pro-
portion of patients with severe allergic asthma having
allergy to a perennial form of aeroallergens (in the cross-
sectional phase) and the proportion of patients with asthma
control at months 6 and 12 with omalizumab therapy (in
longitudinal phase). Secondary outcomes in the cross-sec-
tional phase were the level of asthma control, patient
disease perception, quality of life and healthcare resource
utilization. In the longitudinal phase, secondary variables
were: proportion of patients with at least 1 episode of
asthma exacerbation during the 12-month study period,
Figure 1 PROXIMA study design.
Notes: * Patients with diagnosis of severe asthma, GINA 4, and who Need therapeutic step up.
Dovepress Canonica et al
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patient compliance to omalizumab, persistence with oma-
lizumab treatment, quality of life and healthcare resource
utilization.
Asthma disease control was assessed by the Asthma
Control Questionnaire (ACQ); Brief Illness Perception
Questionnaire (Brief IPQ) and EuroQoL-5 Dimension
(EQ-5D) were used to estimate patient disease perception
and quality of life, respectively. Patient compliance was
assessed as the ratio between the number of injections of
omalizumab administered during the observational period
over the total number of planned injections. Omalizumab
persistence during the 12 months was assessed by Kaplan-
Meier survival curve analysis, where the event of interest
was the treatment discontinuation over the total number of
planned injections. Asthma exacerbations, serum IgE
levels and FEV1 percent were measured by using standard
clinical and laboratory assessment methods.49 The con-
sumption of healthcare resources was evaluated by using
a questionnaire collecting for each patient information on
the number of hospitalizations, number of emergency
department visits, number of outpatient visits and number
of laboratory and diagnostic tests.
Economic Evaluation Assessments
Our analysis focused on healthcare resource use and qual-
ity of life data collected in the observational study, in order
to assess the variation of these outcomes after the admin-
istration of omalizumab compared to baseline treatment
and to evaluate the economic value of omalizumab in the
Italian healthcare setting from INHS perspective. A cost-
utility analysis (CUA) was performed considering total
cost related to severe asthmatic patients’ treatment, as
cost data and quality-adjusted life-years (QALYs), derived
from QoL estimation, as utility measure. Results were
expressed using the incremental cost-effectiveness ratio
(ICER). When the value of a new therapeutic option
needs to be assessed, the ICER provides the additional
resources that have to be used to achieve the additional
benefit. ICER is the difference in cost (ΔC) divided by the
difference in effect (ΔE) between two alternatives.50 The
effectiveness indicator used to compare the pre-post oma-
lizumab period was QALYs calculated from the utilities
obtained from the EQ-5D questionnaire. ICERs were cal-
culated by dividing the difference in direct costs by the
difference in QALYs (effectiveness measure) between post
omalizumab and pre-omalizumab phase.
ICER ¼
Costs post omalizumabð Þ
Costs pre omalizumabð Þ
Effectiveness post omalizumabð Þ
Effectiveness pre omalizumabð Þ
To define a treatment as cost-effective, ICER has to fall
below a given cost per QALY threshold.47,51 The ICER
per QALY gained accepted differs from country to coun-
try. The threshold set by NICE is about £20,000–30,000.52
Although no officially established value is available for
Italy, it is worth noting that recent guidelines by the Italian
Health Economics Association (AIES)53 recommend that a
threshold of €25,000–40,000 be adopted. Other acceptable
references of cost-effectiveness for the Italian context are
€36,500 and €60,000 and have been calculated by two
different authors.54,55
Costs and Quality of Life Utilities
We considered asthma-related healthcare resource utilization
and QoL data collected at baseline and at 12 months after the
initiation of omalizumab. The outcomes were: number of
hospitalizations and/or emergency department visits, outpati-
ent visits and EQ-5D questionnaire results. Pharmacological
treatments costs and OCS adverse events-related costs were
also included in the healthcare–resource consumption analy-
sis. Healthcare resources consumed were converted into eco-
nomic values adopting the perspective of the National Health
Service and frequency of use from PROXIMA study.
Hospitalizations and ER accesses were valued according to
the National Diagnosis-Related Group (DRG) system;56 in
detail, admission due to moderate/severe bronchitis and
asthmawithout complications (€1832), admission due tomod-
erate/severe bronchitis and asthmawith complications (€2537)
and admission due to respiratory insufficiency (€3802) were
considered (DRG code 97, 96, 87). Physician’s visit cost was
derived from National Tariffs (€20.66).57 Drug costs were
obtained considering ex-factory prices (with −5–5% manda-
tory rebates)58 daily dose and duration of administration
according to indications reported in package leaflet and clin-
ical practice guidelines for the management of adult asthma.
Medications for respiratory disease examined were: inhaled
corticosteroids (ICS), long-acting β2 agonist (LABA), short-
acting β2 agonists (SABA), inhaled corticosteroids plus β2
agonists fixed combination, leukotriene modifiers, theophyl-
line and oral corticosteroids (OCS).
To calculate omalizumab cost, ex-factory price
(−5%, −5%) of a 150 mg subcutaneous vial, €333.56,58
(GU – Farmadati Italia) and the mean number of vials per
Canonica et al Dovepress
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patient per 4 weeks, estimated at 2.8 (based on sales data)
were taken into account.
OCS adverse events-related costs were calculated con-
sidering event rates reported in a UK respiratory database
(Optimum Patient Care Research Database, OPCRD)59,60
and comorbidities were valued according to the Diagnosis-
Related Group (DRG) system.
The analysis conducted is a cost–utility analysis, an eco-
nomic evaluation that estimates the cost per quality-adjusted
life-year (QALY) gained from undertaking one intervention
instead of another.61 Utility values were obtained from
the PROXIMA study by using the EuroQol-5 Dimension
(EQ-5D) health status self-assessment questionnaire and qual-
ity-adjusted life years (QALYs) were calculated.
Utilities were used to consider the impact of treatment
on the quality of life. Utility values were expressed on a
numerical scale where the extreme values were 0 and 1,
with 0 representing the worsen status (death) and 1 repre-
senting the best status (perfect health). If the quality of life
worsens, the utilities and QALYs are reduced. Then,
QALYs are overall measures of health outcomes that
weight the life expectancy of patients with an estimate of
their health-related quality of life score.
Statistical and Sensitivity Analysis
In PROXIMA study the statistical analysis for the longitudi-
nal phase was performed considering all evaluable patients
who started the omalizumab therapy as per clinical practice
at baseline with the foreseen time window (±15 days).
Descriptive statistics of hospitalization number, ER visits,
outpatient visits and pharmacological therapies were pro-
vided. (Quantitative variables were described using mean
and standard deviation (SD), and categorical variables were
reported using frequencies and percentages). Moreover, the
distribution of patients according to the answers given to the
EQ-5D items was given. As regard the pharmacoeconomic
analysis, in order to evaluate the uncertainty around the real
direct cost of omalizumab paid by hospitals, we tested the
effects of four increasing discount rates applied to ex-factory
price (20%, 25%, 30%, 35%).
Results
365 patients were enrolled in the PROXIMA study, 130
entered the longitudinal phase, 7 of them were excluded
due to a violation of the inclusion criteria. The final
sample for longitudinal phase included 123 patients: 76
(61.8%) were female and mean±SD age at enrollment was
52.7 (13.6) years. Further demographic and baseline data
are shown in Table 1.
Effectiveness and Resource Consumption
Outcomes
As an evidence of omalizumab effectiveness in terms of
asthma control, a significant decrease in ACQ total score has
been observed at 12 months with a mean±SD change of 1.4
±1.1 (p< 0.0001) with respect to baseline visit with a mean
±SD ACQ score of 2.9±1.1. The number of exacerbations per
patients, recorded over 1 year, showed an average decrease of
−4.0±4.2 (0.6±1.2 exacerbation at 12 months vs 4.6±4.1 at
baseline) which means a reduction of exacerbations of 87% vs
baseline. During the 12-month period of observation, the
Table 1 Baseline Characteristics of the Longitudinal Population
Characteristics Longitudinal
Population (N=123)
Sex
Female 76 (61.8%)
Male 47 (38.2%)
Race
Caucasian/White 117 (95.1%)
Black 3 (2.4%)
Asian/Oriental 3 (2.4%)
Age mean (SD)
Mean (SD) 52.7 (13.6)
Asthma duration years (SD)
Mean (SD) 19.8 (14.5)
Age at diagnosis (SD)
Mean (SD) 32.7 (15.8)
Number of exacerbations in 12-
month prior enrollment
Mean (SD) 4.6 (4.1)
FEV 1
Mean (SD) 1.7 (0.7)
IgE serum level IU/Ml
Mean (SD) 409.3 (394.1)
Occupational status
Unemployed 28 (22.8%)
Employed 68 (55.3%)
Retired 27 (22.0%)
Smoking status
Non-smoker 90 (73.2%)
Former smoker 27 (22%)
Current smokers 6 (4.9%)
Dovepress Canonica et al
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proportion of patients who had experienced at least one asthma
exacerbation resulted in 27.27%, 33 patients over 123, [95%
CI, 19.57%-36.12%], while the proportion of patient with at
least one asthma exacerbation during previous year at baseline
was 87.6%. Patient’s compliance with omalizumab treatment
in the PROXIMA study was considerably high, since the
majority of patients (72.2%) never interrupted omalizumab
during the 12-month observational period, and only nine
patients discontinued omalizumab permanently. According to
the results obtained by means of the EQ-5D questionnaire,
there was a consistent increase in patient’s quality of life after
12 months from enrollment visit. Indeed, the proportion of
patients reporting no problems on the five dimensions of the
EQ-5D (mobility, self-care, usual activities, who did not have
pain or discomfort, and anxiety or depression), increased from
baseline to 12-month follow-up visit. Omalizumab adoption,
as add-on therapy, resulted in a greater effectiveness than pre-
omalizumab treatment involving 0.132 QALYs gained [0.630
(0.642–0.618) vs 0.762 (0.768–0.755)], Figure 2. Moreover, a
significant decrease in medical resources utilization during the
period of treatment with omalizumab was observed. During
the 12-month period of observation, reductions in concomitant
pharmacological treatments were recorded, in particular,
46.4% and 14.3% of patients treated with oral corticosteroids
suspended or reduced the therapy, respectively. From the base-
line, the number of hospitalization (58) and physician’s visits
(482) diminished at 12-month follow-up (3 and 71, respec-
tively). Total number of hospitalization and/or ER access per
patient, due to moderate/severe bronchitis and asthma with/
without complications or due to respiratory insufficiency
decreased from 0.480 at baseline to 0.029 at 12-month fol-
low-up (only 3 admission due to respiratory insufficiency).
Economic Outcomes
The impact of omalizumab treatment on resource con-
sumption involved a significant decrease in healthcare
resource costs (Table 2). Omalizumab effectiveness in
terms of disease control and risk reduction was reflected
also in savings mainly related to a decrease in number of
hospitalizations/ER accesses. Indeed, at 12-month follow-
up costs per patient related to hospitalization and ER
accesses decreased by €2475 compared with pre-omalizu-
mab period. Reduction in pharmacological treatment costs
and medical visit costs amounted to about €385 and €150,
respectively. Furthermore, by adjusting OCS adverse event
rates provided by Sweeney et al60 to PROXIMA data on
OCS use, and quantifying adverse events based on DRG
system, OCS adverse event-related costs were calculated:
after 12 months of omalizumab treatment were about €718
lower than at baseline due to reduction in OCS consump-
tion reported in post-omalizumab period. Total healthcare
resource costs per patient amounted to about €779 after 12
months of omalizumab treatment and € 4508 for the pre-
omalizumab period. The reduction of direct healthcare
costs was €3729 per patient, associated with omalizumab
adoption excluding the add-on treatment cost.
The cost of omalizumab per patient-year was
€11,207.62, obtained from ex-factory price (€333.56) and
mean monthly administration (2.8 vials). By the addition of
omalizumab cost, total direct healthcare costs per patient
resulted in €11,986 determining a €7478 increase in costs
with respect to pre-omalizumab period (€11,986 vs € 4508).
Based on the difference in total direct cost (€7478) and
difference in QALY (0.132) between post and pre-omalizu-
mab period, the ICER was €56,847. Although omalizumab
led to the improvement in effectiveness in terms of quality
of life and reduction in healthcare resource consumption, its
acquisition cost was only partially offset by the reduction in
healthcare resource cost, making a significant impact on
cost-effectiveness evaluation in our analysis. It is important
to note that we calculated omalizumab cost based on ex-
factory price, although it is not the real drug cost paid by
health facilities in Italy as a confidential discounted price is
usually negotiated between manufacturers and Italian NHS.
In order to test the cost-effectiveness of omalizumab by
adopting a discounted price closer to the real one, we
carried out a sensitivity analysis assuming four feasible
scenarios with increasing discounts on price from 20% to
35%. In all scenarios, the ICER resulted below the accepted
threshold (Table 3, Figure 3).
Figure 2 Effects of omalizumab treatment on health-related quality of life: pre-post
omalizumab period comparison (EQ-5D).
Canonica et al Dovepress
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Discussion
This analysis evaluated the economic value of omalizumab
in the treatment of adult patients with severe allergic asthma
(step 4 GINA) in an Italian setting based on real-world data
from the PROXIMA observational study. Since the con-
firmed therapeutic value of this treatment option, we focused
on the impact of omalizumab on healthcare resource con-
sumption and patient’s quality of life. In the observational
study omalizumab effectiveness, in terms of asthma control,
was supported by significant decrease in ACQ total score and
exacerbations reduction of 87% at 12-month follow-up with
respect to baseline. Moreover, during the observational per-
iod, there was a significant decrease in medical resource
utilization, especially hospitalizations. As regard quality of
life, EQ-5D results proved significant improvement during
the 12-month observational period.
The clinical results are consistent with those published in
previous clinical trials and observational studies. The signif-
icant reduction in the number of exacerbations supports the
results from a recent Italian observational study62 in which
more than 50% of patients did not report any exacerbations
during the year of treatment. Moreover, PROXIMA findings
are in agreement with those provided by large studies, such as
eXpeRience observational registry34 and Asterix observa-
tional study.36 Data on oral corticosteroids consumption
reported in PROXIMA Study (46.4% and 14.3% of patients
treated with oral corticosteroids suspended and reduced,
respectively, the therapy during the observational period)
were also consistent with results of previous studies.31,35,62
In eXpeRience observational registry was observed a
similar reduction in maintenance oral corticosteroid use in
uncontrolled persistent allergic asthma patients treated
with omalizumab for 12 months: 40.2% and 16.4% of
patients stopped or reduced the dose of oral corticoster-
oids, respectively.31,34
Another observational, retrospective study evaluating
the real-world effects of omalizumab in UK35 reported
analogous results, 48.5% stopped oral corticosteroids
within 1 year after omalizumab initiation. Moreover, a
systematic review including 24 real-life effectiveness stu-
dies highlighted significant dose reductions in OCSs in
association with omalizumab treatment: estimates of OCS
dose reductions at 1 year were from −12% to −50%, with a
decline of −66% at 2 years.63
The PROXIMA results, in line with the literature, thus
confirm the OCS-sparing effect of omalizumab.
As shown in the literature, regular use of OCS therapy is
linked to the onset of various comorbidities, ranging from
minor effects to severe and potentially life-threating diseases
such as diabetes, cardiovascular disorders and adrenal
suppression.60,64–67 In turn, these corticosteroid-induced
morbidities operate a significant healthcare and economic
burden, also impacting patient’s quality of life.68,69
Table 3 Incremental Cost-Effectiveness Results: Sensitivity
Analysis with Increasing Discounts on Omalizumab Price
Scenario ΔC ΔE ICER
Scenario 1 oma price – 20% € 5236.59 0.132 € 39,807.62
Scenario 2 oma price – 25% € 4676.21 0.132 € 35,547.71
Scenario 3 oma price – 30% € 4115.83 0.132 € 31,287.80
Scenario 4 oma price – 35% € 3555.45 0.132 € 27,027.89
Table 2 Effects of Omalizumab Treatment on Healthcare Resource Costs: Pre and Post Omalizumab Treatment Comparison
Parameters Pre-Omalizumab Post-Omalizumab Δ (Post vs Pre)
Concomitant pharmacological treatments € 731.25 € 346.17 -€ 385.08
Hospitalizations and ER accesses € 2585.68 € 110.26 -€ 2475.42
Medical visits € 164.58 € 14.38 -€ 150.20
OCS adverse events € 1026.86 € 308.06 -€ 718.80
Total € 4508.37 € 778.87 -€ 3729.50
Figure 3 Incremental cost-effectiveness results: sensitivity analysis.
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Indeed, in our study, the costs associated with the
adverse events of corticosteroids, together with those
related to hospitalizations, represented the main cost
items in the pre-omalizumab period. In view of the high
prevalence of corticosteroid related co-morbidities and
their economic consequences, the OCS-sparing effect of
newer asthma treatments such as omalizumab can find
positive implications. By referring to Italy, clinical and
economic implications can be investigated more carefully
when data from ongoing observatory project, SANI
(Severe asthma network in Italy, a web-based registry
collecting data on severe asthmatics, recruited by Italian
Unit of Allergy and Pulmonology) will be available.14
In our analysis, the decrease in healthcare resources
reported in PROXIMA study was converted into economic
values from the perspective of the National Health Service
(NHS): compared to pre omalizumab period a €3,729.50 per
patient reduction in direct healthcare costs was shown after the
omalizumab adoption, excluding the add-on treatment cost.
Nevertheless, the addition of omalizumab acquisition cost
comported considerable increase in healthcare expenses
(€11,207), only partially off-set by resource savings men-
tioned. Therefore, omalizumab improved clinical and health-
related quality of life outcomes of SA patients, but with a
major cost to the Italian NHS considering the ex-factory price
for omalizumab. This performance is typical of innovative
therapies and cost-effectiveness analyses are important tools
to assess value for money and to position new health technol-
ogies by comparing costs and additional benefits. Incremental
cost-effectiveness ratio (ICER) was calculated considering
total incremental healthcare cost per QALY gained between
post- and pre-omalizumab period: the ICER was sensitive to
omalizumab cost. Adopting omalizumab ex-factory price
(−5%,-5%), we obtained an ICER of €56,847, above the
commonly accepted threshold in Italy. In contrast, assuming
a discounted price negotiated between manufacturer and
National Health Service, detail of which are confidential, we
calculated theminimum discount necessary to achieve a favor-
able cost-effectiveness threshold. Omalizumab represented a
cost-effective use of Italian NHS resources already at 20%
discounted price reporting an ICER of €39,807 and increas-
ingly favorable with increased discounts assumed in the ana-
lysis (25%, 30%, 35%), until ICER of € 27,027 assuming a
35% discounted price. In line with our considerations, other
studies highlighted that the cost-effectiveness of omalizumab
is highly sensitive to price assumptions and improvement in
health-related quality of life.70–72 Several studies on the cost-
effectiveness of omalizumab have been published in the
international literature, both based on RCTs and observational
studies, and a difference in the ICER estimation was observed
related to difference in study design, population at baseline and
drug unit cost.70–76 One economic evaluation conducted in the
UK considered the cost-effectiveness of omalizumab under
the list price and Patient Access Scheme (PAS) discounted
price for the UK NHS. The incremental cost-effectiveness
ratio varied from £30,109 to £57,557 per QALY gained
depending on the population considered using the PAS price;
incremental cost-effectiveness ratios were over a third higher
using the list price. The ICERs were lower in subgroup ana-
lyses of patients hospitalized in the year prior to trial entry, and
in patients receiving maintenance oral corticosteroids at base-
line due to a greater improvement in health-related quality of
life.70 This analysis supports our findings, although it was
based on a cohort Markov model, while we considered real-
world data from an observational study. Real-world evidence
is becoming increasingly important in reimbursement deci-
sions, and health care decision makers are developing policies
that integrate data from different sources, recognizing the
importance of evidence that goes beyond the information
collected within the framework of clinical trials.77 Economic
evaluation studies that incorporate real-world evidence are of
major importance and provide added value to the evidence
considered by decision makers, as these reflect the effective-
ness of pharmaceutical products in real-life and illustrate how
these last translate into the drug’s economic value for patients’
lives.78 Omalizumab improves asthma control in patients with
uncontrolled severe allergic asthma, however, due to the high
cost of the drug, accurate selection of patients with SA is
crucial in the management of the disease.79–81 The identifica-
tion of biomarkers predictive of response is of major impor-
tance for future research. Indeed, it can contribute to
minimizing unnecessary drug exposure and health care costs
for non-responders.72,73,82 Omalizumab response prediction
methods, such as genetic text, may support clinical decisions,
in this respect, PROXIMA sub-study results may help in the
identification and characterization of super responder patients
to this therapy and lead in the future to a tailored-made
approach medicine. Our analysis also has assumptions and
limitations. PROXIMA observational study provided clinical
data, this design has intrinsic limitations inherent in the used
data and potential selection bias. However, the inclusion and
exclusion criteria of the PROXIMA study were defined in
order to represent omalizumab adult patients in participating
centers. Patients started a therapy with omalizumab within the
time windows between 15 days before enrollment and 90 days
after enrollment. The study results can be generalized to the
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adult population of severe asthmatic Italian patients in GINA
step 4 and needed a therapeutic step up. Our analysis consid-
ered only direct costs in line with the Italian NHS perspective.
This is a limit of the study; indeed the burden of indirect costs
associated with severe asthma is significant, as reported in
several studies.31,83 Therefore, it would be interesting to plan
further analyses taking account of total cost, to define the
socioeconomic impact of disease. Furthermore, in our analy-
sis, no adverse events from omalizumab were included, while
events related to the long-term use of maintenance OCS were
considered given their significant cost and HRQOL implica-
tion. Rates of OCS-related events derived from a UK database
study;60,69 these rates were used to calculate savings provided
by the steroid-sparing effect of omalizumab reported after 12-
month follow-up. Although these prevalence data were not
related to Italy, pending national results, were generalizable
and have been good support for our evaluation.
Conclusion
PROXIMA study demonstrated the effectiveness of oma-
lizumab treatment in severe allergic asthma in step 4
GINA requiring a therapeutic step up. It showed to
improve symptoms proving decreased incidence of exacer-
bations, number of hospitalizations, physician visits and
better quality of life after 12 months of treatment.
Moreover, it allowed a remarkable reduction in systemic
corticosteroids use. Our economic evaluation assessed
omalizumab value for money: omalizumab effectiveness
was reflected in a reduction of resources for Italian NHS,
although higher treatment costs resulted in a cost-effec-
tiveness of €56,847 per QALY that exceeds value thresh-
olds. Nevertheless, the cost-effectiveness of €40,000 per
QALY would be already achieved with a 20% price dis-
count, making omalizumab a sustainable innovative treat-
ment option for patients with uncontrolled allergic asthma.
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